Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Ruben Pio

Professor

Universidad de Navarra

Spain

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Academic Page

Research Interests

Immunology

70%

Biostatistics

30%

Cancer Biology

90%

Inflammatory Biology

30%

Tumor Suppressor

30%

Cancer Diagnosis

20%

Genomic

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Close

INGENIO (INtegrative GENomic, digital Imaging and clinical information towars Precision Oncology Optimization)

Open Date: 2022-01-01

Close Date: 2025-01-01

Grant: Close

Caloric restriction as a tool to enhance the efficacy and minimize the toxicity of immunotherapy against lung cancer

Open Date: 2022-01-01

Close Date: 2024-01-01

Grant: Close

New biomarkers for a personalized determination of lung cancer risk in low-dose CT screening protocols: development and validation of high-sensitivity protein signatures in combination with radiomic analysis

Open Date: 2022-01-01

Close Date: 2024-01-01

Grant: Close

Modulation of the complement system to improve antitumor activity and decrease side effects of immunotherapy against lung cancer

Open Date: 2021-01-01

Close Date: 2023-01-01

Grant: Close

Discovering immune therapeutic vulnerabilities in KRAS/STK11-mutant lung adenocarcinomas

Open Date: 2020-01-01

Close Date: 2022-01-01

Articles20

Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors.

Article Link

Year:

2025

Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer.

Article Link

Year:

2025

The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response.

Article Link

Year:

2025

Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

Article Link

Year:

2024

The complement system in clinical oncology: Applications, limitations and challenges.

Article Link

Year:

2024

G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1.

Article Link

Year:

2024

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.

Article Link

Year:

2024

Fasting and fasting-mimicking conditions in the cancer immunotherapy era.

Article Link

Year:

2024

Elevated expression of complement factor I in lung cancer cells associates with shorter survival-Potentially via non-canonical mechanism.

Article Link

Year:

2024

Plasma fractalkine contributes to systemic myeloid diversity and <scp>PD‐L1</scp>/<scp>PD</scp>‐1 blockade in lung cancer

Article Link

Year:

2023

Tumor ENPP1(CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer.

Article Link

Year:

2022

Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis.

Article Link

Year:

2021

Two alternative cell line models for the study of multiorganic metastasis and immunotherapy in Lung Squamous Cell Carcinoma.

Article Link

Year:

2021

Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge.

Article Link

Year:

2021

The Complement System in Ovarian Cancer: An Underexplored Old Path

Article Link

Year:

2021

A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

Article Link

Year:

2021

Molecular biomarkers in early stage lung cancer

Article Link

Year:

2021

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Article Link

Year:

2021

Surgical Outcomes in a Lung Cancer-Screening Program Using Low Dose Computed Tomography,Resultados quirúrgicos de un programa de cribado de cáncer de pulmón utilizando tomografía computarizada de baja dosis

Article Link

Year:

2021

Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

Article Link

Year:

2021

Collaborators14

Marta Santisteban

Clinica Universidad de Navarra

SPAIN

Ana Patiño-García

Clinica Universidad de Navarra

SPAIN

Diego Serrano

Universidad de Navarra

SPAIN

marisol gonzalez-huarriz

Clinica Universidad de Navarra

SPAIN

Victor Segura

Universidad de Navarra

SPAIN

Jose Maria Lopez-Picazo

Associate professor, accreditation required

Universidad de Navarra

SPAIN

Eloisa Jantus Lewintre

Profesora titular

Universitat Politècnica de València

SPAIN

Maria Jose Pajares

Professor

Public University of Navarre

SPAIN

Graziella Bosco

University of Cologne

GERMANY

Cristina Bértolo

Universidad de Navarra

SPAIN

Jose Yuste

Profesor

Universidad de Navarra

SPAIN

Nerea Varo

Clinica Universidad de Navarra

SPAIN

Juan Berto

Clinica Universidad de Navarra

SPAIN

Daniel Ajona

Assistant Professor

Universidad de Navarra

SPAIN

How do I reach out?

Meet Kite AI